Invention Grant
US09040557B2 Composition containing cinchonine as an active ingredient for preventing and treating obesity, dyslipidemia, fatty liver, or insulin resistance syndrome
有权
含有辛可宁作为预防和治疗肥胖，血脂异常，脂肪肝或胰岛素抵抗综合征的活性成分的组合物
- Patent Title: Composition containing cinchonine as an active ingredient for preventing and treating obesity, dyslipidemia, fatty liver, or insulin resistance syndrome
- Patent Title (中): 含有辛可宁作为预防和治疗肥胖，血脂异常，脂肪肝或胰岛素抵抗综合征的活性成分的组合物
-
Application No.: US13578717Application Date: 2010-12-14
-
Publication No.: US09040557B2Publication Date: 2015-05-26
- Inventor: Tae Sun Park
- Applicant: Tae Sun Park
- Applicant Address: KR Incheon
- Assignee: YONSEI UNIVERSITY TECHNOLOGY HOLDINGS, INC.
- Current Assignee: YONSEI UNIVERSITY TECHNOLOGY HOLDINGS, INC.
- Current Assignee Address: KR Incheon
- Agency: Clark & Elbing LLP
- Priority: KR10-2010-0004901 20100119
- International Application: PCT/KR2010/008944 WO 20101214
- International Announcement: WO2011/090265 WO 20110728
- Main IPC: A61K31/4409
- IPC: A61K31/4409 ; A61K31/47 ; A61K31/4709 ; A61K31/49 ; A61K31/439
Abstract:
The present invention relates to a composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising cinchonine as an active ingredient. The composition of the present invention comprising cinchonine as an active ingredient contributes to not only inhibition of adipocyte differentiation but also reductions of body weight, visceral fat, total cholesterol level, plasma triglyceride level and liver tissue triglyceride level, thereby exerting prevention or treatment efficacies of obesity, hyperlipidemia or fatty liver. In addition, the composition of the present invention induces significant decrease in fasting glucose level and blood insulin level to improve type 2 diabetes, insulin resistance and related metabolic diseases.
Public/Granted literature
Information query
IPC分类:
